Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.

Date publication

avril 2018

Journal

Journal of Crohn's & colitis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, Barclay ML, Colombel JF, Lopez A, Beaugerie L, Marinaki AM, van Bodegraven AA, Neurath MF

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29293971

Résumé

Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free remission in patients with inflammatory bowel disease. To provide a state-of-the-art overview of thiopurine treatment in inflammatory bowel disease, this clinical review critically summarises the available literature, as assessed by several experts in the field of thiopurine treatment and research in inflammatory bowel disease.

Mots clés

Azathioprine, pharmacology, Drug Therapy, Combination, Gastrointestinal Agents, therapeutic use, Humans, Immunosuppressive Agents, pharmacology, Inflammatory Bowel Diseases, drug therapy, Infliximab, therapeutic use, Mercaptopurine, pharmacology, Neoplasms, epidemiology, Risk Factors, Thioguanine, pharmacology

Référence

J Crohns Colitis. 2018 Apr 27;12(5):610-620